200 related articles for article (PubMed ID: 11914880)
1. FDG PET in the management of lymphoma: a clinical perspective.
Hoskin PJ
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
[No Abstract] [Full Text] [Related]
2. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
Spaepen K; Stroobants S; Verhoef G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in the management of lymphomas: a summary.
O'Doherty MJ; Hoskin PJ
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S128-30. PubMed ID: 12692689
[No Abstract] [Full Text] [Related]
5. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
6. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
[No Abstract] [Full Text] [Related]
7. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
Kaplan LD
Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
[No Abstract] [Full Text] [Related]
11. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
13. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC
J Clin Oncol; 2015 Apr; 33(10):1217. PubMed ID: 25691675
[No Abstract] [Full Text] [Related]
14. The role of PET imaging in lymphoma.
Burton C; Ell P; Linch D
Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
[TBL] [Abstract][Full Text] [Related]
15. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
16. FDG positron emission tomography in lymphoma.
Tecnologica MAP Suppl; 2000 Jan; ():9-10. PubMed ID: 10848116
[No Abstract] [Full Text] [Related]
17. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
18. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
19. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
[No Abstract] [Full Text] [Related]
20. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]